It has been shown that anti-PD-1/PD-L1 inhibitor monotherapies or in combination with platinum-based chemotherapies improved patients’ survival in metastatic NSCLC regardless of PD-L1 expression in the tumor [36,37,38,39]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.